Key Points
- Omnicell EVP Nnamdi Njoku sold 3,090 shares on May 18 at an average price of $43.22, for proceeds of about $133,550. The sale reduced his position by 1.96% and was made under a pre-arranged 10b5-1 plan to cover tax withholding from vested equity awards.
- Omnicell recently beat earnings expectations, reporting $0.55 EPS versus the $0.33 consensus, while revenue rose 14.9% year over year to $309.88 million. The company also issued FY2026 EPS guidance of 1.80 to 2.00.
- Analyst sentiment remains broadly positive, with one Strong Buy, seven Buy ratings, and one Hold rating. The stock’s average price target is $59.86, above its recent trading price around $43.82.
Omnicell, Inc. (NASDAQ:OMCL - Get Free Report) EVP Nnamdi Njoku sold 3,090 shares of Omnicell stock in a transaction on Monday, May 18th. The shares were sold at an average price of $43.22, for a total value of $133,549.80. Following the completion of the transaction, the executive vice president owned 154,785 shares in the company, valued at $6,689,807.70. The trade was a 1.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Omnicell Price Performance
Shares of Omnicell stock opened at $43.82 on Wednesday. Omnicell, Inc. has a twelve month low of $26.84 and a twelve month high of $55.00. The stock has a market capitalization of $1.99 billion, a P/E ratio of 99.59, a PEG ratio of 1.12 and a beta of 0.96. The company has a current ratio of 1.50, a quick ratio of 1.29 and a debt-to-equity ratio of 0.13. The business's fifty day moving average price is $37.71 and its 200 day moving average price is $40.60.
Omnicell (NASDAQ:OMCL - Get Free Report) last issued its earnings results on Tuesday, April 28th. The company reported $0.55 earnings per share for the quarter, beating analysts' consensus estimates of $0.33 by $0.22. The firm had revenue of $309.88 million for the quarter, compared to analysts' expectations of $304.02 million. Omnicell had a return on equity of 4.00% and a net margin of 1.67%.The firm's revenue for the quarter was up 14.9% compared to the same quarter last year. During the same quarter last year, the firm earned $0.26 earnings per share. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. As a group, research analysts anticipate that Omnicell, Inc. will post 1.31 earnings per share for the current year.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the business. Cerity Partners LLC lifted its stake in shares of Omnicell by 4.9% in the fourth quarter. Cerity Partners LLC now owns 7,613 shares of the company's stock worth $345,000 after acquiring an additional 354 shares in the last quarter. SG Americas Securities LLC lifted its stake in shares of Omnicell by 6.6% in the third quarter. SG Americas Securities LLC now owns 6,433 shares of the company's stock worth $196,000 after acquiring an additional 401 shares in the last quarter. Thrivent Financial for Lutherans lifted its stake in shares of Omnicell by 1.2% in the second quarter. Thrivent Financial for Lutherans now owns 34,445 shares of the company's stock worth $1,013,000 after acquiring an additional 424 shares in the last quarter. Martin & Co. Inc. TN lifted its stake in shares of Omnicell by 0.4% in the third quarter. Martin & Co. Inc. TN now owns 121,720 shares of the company's stock worth $3,706,000 after acquiring an additional 443 shares in the last quarter. Finally, Legal & General Group Plc lifted its stake in shares of Omnicell by 0.3% in the third quarter. Legal & General Group Plc now owns 158,399 shares of the company's stock worth $4,823,000 after acquiring an additional 448 shares in the last quarter. Institutional investors and hedge funds own 97.70% of the company's stock.
Analysts Set New Price Targets
A number of research analysts have commented on OMCL shares. Benchmark restated a "buy" rating on shares of Omnicell in a research note on Friday, March 13th. Zacks Research upgraded Omnicell from a "hold" rating to a "strong-buy" rating in a research note on Friday, May 1st. Piper Sandler restated an "overweight" rating and set a $49.00 price objective (down from $63.00) on shares of Omnicell in a research note on Friday, February 6th. UBS Group set a $60.00 price objective on Omnicell and gave the stock a "buy" rating in a research note on Friday, March 13th. Finally, Wall Street Zen upgraded Omnicell from a "buy" rating to a "strong-buy" rating in a research note on Sunday, May 10th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $59.86.
Get Our Latest Stock Report on OMCL
About Omnicell
(
Get Free Report)
Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company's offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell's analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.
Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
